Article

Seven COVID-19 Patients Treated with C-Reactive Protein (CRP) Apheresis

2022-03-02

Abstract excerpt

<h4>Background: </h4> The fulminant course of COVID-19, triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents with a high mortality rate and still lacks a causative treatment. C-reactive protein (CRP) has been shown to increase dramatically during the disease progression and correlates with deleterious outcomes. Selective CRP apheresis can reduce circulating CRP levels fast and effecti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fd19551e-7870-564b-a54b-55ea743db5c1
DOI: 10.20944/preprints202203.0029.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Seven COVID-19 Patients Treated with C-Reactive Protein (CRP) ApheresisDOI 10.20944/preprints202203.0029.v1Read

Features of C-reactive protein in COVID-19 patients within various period: a cohort studySemantic proximity Read

Kinetics of C-reactive Protein and Procalcitonin in the Early Identification of ICU-Acquired Infections in Critically Ill COVID19 PatientsSemantic proximity Read

Features of C-reactive protein in COVID-19 patients with different ages, clinical types and outcomes: a cohort studySemantic proximity Read

On whether therapeutic plasma exchange is an effective cure against severe/critical COVID-19 pneumoniaSemantic proximity Read

On Whether Therapeutic Plasma Exchange is Effective Against Severe/Critical COVID-19 PneumoniaSemantic proximity Read

Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facilitySemantic proximity Read

Efficacy and safety of convalescent plasma therapy for severe COVID-19 patients：case series study and literature reviewSemantic proximity Read

Challenges in the Clinical Management of SARS-CoV2-Infected Patients with Haematological MalignanciesSemantic proximity Read

COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trialSemantic proximity Read

Early suPAR-Guided Anakinra Treatment in COVID-19 Pneumonia: Subgroup Analyses and 90-Day Outcomes of the SAVE-MORE TrialSemantic proximity Read

Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective randomized clinical trialSemantic proximity Read

Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumoniaSemantic proximity Read